IMPROVED REMISSION INDUCTION-RATE WITH D-ZAPO BUT UNIMPROVED REMISSION DURATION WITH ADDITION OF IMMUNOTHERAPY TO CHEMOTHERAPY IN PREVIOUSLY UNTREATED CHILDREN WITH ANLL

被引:43
作者
BAEHNER, RL
BERNSTEIN, ID
SATHER, H
HIGGINS, G
MCCREADIE, S
CHARD, RL
HAMMOND, D
机构
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 1979年 / 7卷 / 02期
关键词
acute nonlymphocytic leukemia; chemotherapy; immunotherapy; prognostic factors;
D O I
10.1002/mpo.2950070206
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 163 children with acute nonlymphocytic leukemia (ANLL), a D-ZAPO induction program consisting of daunomycin, 5-azacytidine, cytosine arabinoside, prednisone and vincristine resulted in a remission rate of 71.8%. Immunologic therapy was employed during maintenance with the aim of prolonging remission and improving survival. The administration of immunotherapy consisting of a mixture of BCG and allogeneic acute myelocytic leukemic cells injected intradermally on day 14 of each of the 1st 3 monthly cycles of 6-thioguanine for 10 days, 5-azacytidine and cytosine arabinoside for 4 days and vincristine for 1 day did not improve remission duration or survival compared to that due to chemotherapy alone. Important prognostic factors identified in this study included a remission induction rate significantly better for females than males (P = 0.04) for children between the ages of 5 and 10 yr compared to those greater than this age group (P = 0.01), and a prolonged remission duration (P = 0.04) and survival (P < 0.01) for patients with initial white blood counts of < 20 .times. 109/l.
引用
收藏
页码:127 / 139
页数:13
相关论文
共 32 条
  • [1] Simone J, Aur RJA, Hustu HD, Pinkel D, “Total therapy” studies of acute lymphocytic leukemia in childhood. Current results and prospects for cure, Cancer, 30, (1972)
  • [2] Sather H, Coccia P, Nesbit M, Level C, Hammond D, (1978)
  • [3] Chard RL, Finkelstein JZ, Sonley MJ, McCreadie S, Weiner J, Sather H, Hammond D, Increased survival in childhood acute nonlymphocytic leukemia after treatment with prednisone, cytosine arabinoside, 6‐thioguanine, cyclophosphamide and oncovin (PATCO) combination chemotherapy – 163 patients, Med Pediatr Oncol, 3, (1978)
  • [4] Sonley MJ, Nesbit M, Thatcher LG, Cytosine arabinoside, cyclophosphamide and vincristine in children with acute myelogenous leukemia, Proc Am Assoc Cancer Res, 12, (1977)
  • [5] Evans DIK, Morris Jones PH, Morley CJ, Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunomycin, prednisone and mercaptopurine or thioguanine, Cancer, 36, (1975)
  • [6] Pizzo PA, Henderson ES, Leventhal BG, Acute myelogenous leukemia in children: A preliminary report of combination chemotherapy, J Pediatr, 88, (1976)
  • [7] Karon M, Sieger L, Leimbrock S, Finkelstein JZ, Nesbit ME, Swaney JJ, 5‐Azacytidine: A new active agent for the treatment of acute leukemia, Blood, 42, (1973)
  • [8] VanHoff DD, Slavik M, Muggia FM, 5‐Azacytidine: A new anticancer drug with effectiveness in acute myelogenous leukemia, Ann Int Med, 85, (1976)
  • [9] Mathe G, Amiel SL, Schwarzenberg L, Schneider M, Calton A, Schlumberger JR, Hayath M, DeVassal F, Active immunotherapy for acute lymphoblastic leukemia, Lancet, 1, (1969)
  • [10] Treatment of acute lymphoblastic leukemia. Comparison of immunotherapy (BCG), intermittent methotrexate, and no therapy, after a five‐month intensive cytotoxic regimen (Concord Trial), Br Med J, 4, (1971)